Nanomedicine for Alzheimer's Disease Therapy

Alzheimer’s disease presents formidable challenges due to the impermeability of the blood–brain barrier and the multifactorial nature of its pathology. Nanomedicine leverages nanoscale carriers to address these obstacles by engineering surface functionalities and stimuli-responsive mechanisms for targeted delivery of therapeutic agents. Polymeric, lipid and inorganic nanoparticles can ferry small molecules, peptides or nucleic acids across the barrier, enabling precise intervention against amyloid-β aggregates, tau pathology and neuroinflammation. Multifunctional platforms combine diagnostic imaging with therapy, while novel routes such as intranasal administration offer non-invasive access to the brain. Preclinical studies have demonstrated cognitive improvement through metal-ion chelation, reactive oxygen species scavenging and gene silencing via siRNA. Translational efforts now focus on optimising particle stability, biocompatibility and large-scale manufacturing to realise the global potential of nanomedicine in slowing or halting dementia progression.

Research from Nature Portfolio

Seminal work identified a cyclic peptide that selectively homes to cerebrovascular alterations and reactive astrocytes in Alzheimer’s models. When conjugated to delivery systems, this peptide facilitated targeted transport across the disrupted blood–brain barrier and accumulation at sites of neuroinflammation. This approach has laid groundwork for precision delivery of therapeutic and imaging agents, demonstrating that molecular markers of vascular change can be exploited to enhance nanoparticle recruitment to diseased brain regions.

Nanomedicine for Alzheimer's Disease Therapy publication trend

The graph below shows the total number of articles in nanomedicine for alzheimer's disease therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Blood–brain barrier (BBB): A selective endothelial interface that regulates molecular transport between the bloodstream and the central nervous system.

Amyloid-β (Aβ): Peptide fragments that aggregate extracellularly in the brain to form plaques, a hallmark of Alzheimer’s pathology.

Short interfering RNA (siRNA): Double-stranded RNA molecules that induce sequence-specific gene silencing via the RNA interference pathway.

Polydopamine: Bioinspired polymer mimicking natural melanin, used to create nanoparticles with metal-chelating and antioxidant properties.

Liposome: Spherical vesicle composed of phospholipid bilayers, utilised for encapsulation and targeted delivery of therapeutic agents.

References

1. Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer’s disease. Nature Communications (2017).
2. Pathological BBB Crossing Melanin-Like Nanoparticles as Metal-Ion Chelators and Neuroinflammation Regulators against Alzheimer’s Disease. Research (2023).
3. Nanomedicines for Alzheimer's disease: Therapies based on pathological mechanisms. Brain‐X (2023).
4. In Vivo Evaluation of Nose-to-Brain Delivery of Liposomal Donepezil, Memantine, and BACE-1 siRNA for Alzheimer’s Disease Therapy. International Journal of Molecular Sciences (2024).